USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
A privately-held drug discovery company based in San Diego, USA, has raised $100 million in a series B financing co-led by Ascenta Capital and Abingworth. 5 October 2023
Caught up in the geopolitical tension between China and the West, western pharma multi-national corporations (MNCs) are increasingly cautious about investing in China. 5 October 2023
The UK is in a strong position to become “a global leader in mRNA medicine,” according to a new report by industry cheerleader the BioIndustry Association (BIA). 4 October 2023
California-based Vistagen Therapeutics, a company aiming to transform the treatment landscape for anxiety, depression, and other central nervous system (CNS) disorders, has raised $100 million through an underwritten offering of its common stock. 4 October 2023
Madrigal Pharmaceuticals, a US biopharma pursuing new therapeutics for non-alcoholic steatohepatitis (NASH), has announced the pricing of its underwritten public offering. 2 October 2023
Seattle, USA-based clinical-stage biopharma Avalyn Pharmaceuticals has announced the closing of an oversubscribed $175 million Series C financing. 28 September 2023
A $250 million private financing for California’s BridgeBio Pharma will support a possible launch of acoramidis, as well as further late-stage pipeline development. 26 September 2023
Danish company Acesion Pharma has closed an oversubscribed Series B financing round, raising around 43 million euros ($48 million) to support its work in atrial fibrillation (AF). 26 September 2023
China’s tension between the US-led West, its down-sliding economy and the increasingly wayward policy making all added to the factors that made investors seek different ways to grow their businesses in the country, said speakers at ChinaBio partnering forum held on September 20 in Shanghai. 25 September 2023
A shortening cash runaway and a lack of near-term “value creation prospects” have forced some difficult decisions for Californian cancer firm Kinnate Biopharma. 20 September 2023
With medical research into molecular glues on the rise, research from Harvard University is finding its way into the local biotech scene. 19 September 2023
Shares of Hyderabad, India-headquartered Suven Pharmaceuticals hit a fresh 52-week high on the bourses after the Indian government gave the green signal to foreign direct investment (FDI) of up to $1.15 billion by drug major Cyprus-based Berhyanda. 19 September 2023
South Korean contract development and manufacturing organization (CDMO) Samsung Biologics has announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of the US pharma major’s commercial antibody cancer drug substance. 18 September 2023
A new US biotech, Arialys Therapeutics, which is pioneering new therapeutics for autoimmune neuropsychiatry, has announced the closing of $58 million in seed financing. 15 September 2023
A company founded by Flagship Pioneering, Generate Biomedicines, has raised over a quarter of a billion dollars in a series C financing round. 14 September 2023
Stock in New Jersey, USA-based Rocket Pharmaceuticals shot up around 40% on Wednesday, following good news on the financing and regulatory fronts. 14 September 2023
Taiwan-based BRIM Biotechnology today announced that 22,500 shares have been issued at a premium of NT$65 (~US$2.03), raising a total of NT$1.4625 billion (~US$45.8 million). 13 September 2023
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news